The Shotlee Journal
Expert insights on GLP-1 medications, peptide therapy, and evidence-based approaches to weight management.
Loading articles...
Showing 9 / 1275 articles
The surge in GLP-1 medications is revolutionizing not just health but fashion retail, with 23% of U.S. households now using drugs like Ozempic and Wegovy. This rapid weight loss is shrinking demand for plus-size clothing, pressuring retailers like Torrid and DXL. Yet, opportunities emerge in transitional wardrobes and long-term inclusivity.
More Americans are turning to GLP-1 drugs like Wegovy for weight loss, but experts warn of a critical error. The biggest mistake, says obesity specialist Dr. Katherine Saunders, is treating the prescription as the full treatment. Pairing meds with healthy habits amplifies benefits and sustains results.
The VanEck Pharmaceutical ETF (PPH) offers broad pharma exposure but faces headwinds from U.S. drug pricing reforms and heavy Eli Lilly weighting. Down 8% in the past month despite 15% one-year gains, PPH's diversification is tested. Key risks include MFN pricing deals and GLP-1 competition.
Reports claim jockeys are turning to Ozempic for rapid weight loss, sparking debate on whether semaglutide should join WADA's Prohibited List. With WADA's 2024 Monitoring Program underway and research into performance effects, the drug's potential benefits and risks in sports like cycling and horse racing are under the microscope. Could this GLP-1 agonist redefine fair play in weight-class sports?
India's metabolic therapy market is shifting dramatically after semaglutide's patent expiry, slashing prices by 85-90% and unlocking demand for 75-80 million obese individuals. Ajanta Pharma gears up for generic semaglutide launch, while Sun Pharma leverages innovations for sustained growth. Analysts forecast the GLP-1 segment scaling to INR34-67 billion in 3-5 years amid rising specialist adoption.
In a Phase 2 clinical trial in China, Novo Nordisk's experimental drug UBT251 surpassed Ozempic, achieving greater reductions in blood sugar (up to 2.16% HbA1c drop) and body weight (up to 9.8% loss). This marks a potential advancement for type 2 diabetes management. Patients on semaglutide saw 1.77% HbA1c and 4.8% weight reductions, while placebo groups lagged behind.
Gayle King's dramatic slim-down over the past two years has social media buzzing with Ozempic speculation, especially her facial changes like hollow eyes and sunken cheeks. Plastic surgeon Dr. Michael Omidi breaks down 'Ozempic face' and how to address it. Yet, the CBS star credits Weight Watchers and mindset shifts for her 25-pound loss post-menopause.
Dale, a 38-year-old former army HGV driver, shed pounds on Mounjaro but turned to grey market peptides when prices soared. Inside Discord groups buzzing with rave reviews, he bought unlicensed BPC157 and CJC-1295 with Ipamorelin. This glimpse reveals the booming, risky world of grey market peptide sourcing for weight loss.
Dietary supplement makers are pressing the FDA to broaden ingredient criteria, potentially greenlighting peptides and probiotics not traditionally found in food. A key public meeting highlighted industry pleas under RFK Jr.'s health leadership, sparking debates on safety and oversight. Here's what this means for the booming wellness market.
